NEWS: 公告在東京證券交易所JASDAQ標準市場新上市

市場調查報告書

自體免疫性溶血性貧血治療藥的全球市場:各類藥物,各疾病類型,各流通管道,各地區的,市場規模調查與預測(2020年∼2027年)

Global Autoimmune Hemolytic Anemia Therapeutics Market Size study, by Drug Class, By disease type, by Distribution channel and Regional Forecasts 2020-2027

出版商 Bizwit Research & Consulting LLP 商品編碼 1006310
出版日期 內容資訊 英文
商品交期: 2-3個工作天內
價格
自體免疫性溶血性貧血治療藥的全球市場:各類藥物,各疾病類型,各流通管道,各地區的,市場規模調查與預測(2020年∼2027年) Global Autoimmune Hemolytic Anemia Therapeutics Market Size study, by Drug Class, By disease type, by Distribution channel and Regional Forecasts 2020-2027
出版日期: 2021年05月03日內容資訊: 英文
簡介

全球自體免疫性溶血性貧血治療藥的市場規模在2020年∼2027年間的預測期間內,預計將以超越6.14%的健全的成長率增長。

全球血液病病例數量的增加是推動自身免疫性溶血性貧血治療需求的主要因素之一。此外,預計全球自身免疫性溶血性貧血藥物市場將受到患者宣傳計劃中對聯合療法和貧血藥物生產的需求增加的推動。然而,治療費用是影響治療選擇的主要因素。

這份報告提供自體免疫性溶血性貧血治療藥的世界市場調查,提供市場概要,市場成長要素及阻礙因素分析,市場機會,藥物類別·疾病類型·流通管道·各地區的市場規模的變化與預測,競爭情形,主要企業的簡介等系統性資訊。

目錄

第1章 摘要整理

第2章 市場定義和範圍

第3章 市場動態

  • 市場影響分析(2018年∼2027年)

第4章 產業分析

  • 波特的五力分析
  • PEST分析
  • 投資採用模式
  • 分析師的推薦事項與結論

第5章 各藥物類別

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 皮質類固醇
    • 單株抗體
    • 其他

第6章 各疾病類型

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 冷抗體溶血性貧血
    • 溫抗體溶血性貧血

第7章 各流通管道

  • 市場概述
  • 效能:潛在的分析
  • 市場規模預測:2017年∼2027年(10億美元單位)
  • 子區隔分析
    • 醫院藥局
    • 零售藥局
    • 線上藥局

第8章 世間各地區

  • 地區市場概述
  • 北美
    • 美國
    • 加拿大
  • 歐洲的概述
    • 英國
    • 德國
    • 法國
    • 西班牙
    • 義大利
    • 其他歐洲
  • 亞太地區的概述
    • 中國
    • 印度
    • 日本
    • 澳洲
    • 韓國
    • 其他亞太地區
  • 南美的概述
    • 巴西
    • 墨西哥
  • 其他地區

第9章 競爭資訊

  • 頂級市場策略
  • 企業簡介
    • Kezar Life Sciences, Inc.
    • Amneal Pharmaceuticals, Inc.
    • F. Hoffmann-La Roche Ltd.
    • Rigel Pharmaceuticals, Inc.
    • Baxter International, Inc.
    • Incyte Corp.
    • Teva Pharmaceutical Industries Ltd.
    • Sanofi
    • Pfizer, Inc.
    • Mylan NV

第10章 調查流程

目錄

Global Autoimmune Hemolytic Anemia Therapeutics Market is valued approximately USD XXX million in 2019 and is anticipated to grow with a healthy growth rate of more than 6.14 % over the forecast period 2020-2027. Immune hemolytic anaemia (IHA) is another name for autoimmune hemolytic anaemia (AHA) which is a rare immune red blood cell disease. As the immune system produces antibodies that target the body's red blood cells, autoimmune hemolytic anaemia develops, caused by a reduction in the amount of red blood cells. The rising number of cases of blood disorders around the world is one of the major factors driving demand for autoimmune hemolytic anemia therapeutics. According to Statista, the most common forms of bleeding disorders are haemophilia A and B, as well as von Willebrand disease. In 2018, 210,454 people were diagnosed with haemophilia and 78,500 people were diagnosed with von Willebrand disease around the world. In addition, it is estimated that more than 13,600 people in the United States were diagnosed with haemophilia A in 2018, while only 4,100 were diagnosed with haemophilia B. Additionally, increased use of drugs like corticosteroids for patients with autoimmune hemolytic anaemia is driving the global autoimmune hemolytic anaemia therapeutics sector. To avoid risks such as osteoporosis, diabetes, obesity, and uncontrolled hypertension, corticosteroids are strongly recommended. Also, the global autoimmune hemolytic anaemia therapeutics market is anticipated to be driven by an increase in demand for the production of combination therapies and anaemia therapeutics in patient assistance programmes. However, treatment costs are a major factor influencing the choice of therapy. Bone marrow transplantation costs are over USD 300,000. Thus, high treatment costs are likely to hamper the growth of the market for autoimmune hemolytic anemia therapeutics treatment.

The regional analysis of global Autoimmune Hemolytic Anemia Therapeutics market is considered for the key regions such as Asia Pacific, North America, Europe, Latin America and Rest of the World. North America is the leading region across the world in terms of market share owing to the high prevalence rate of blood disorder. Whereas Asia-Pacific is also anticipated to exhibit highest growth rate over the forecast period 2020-2027. Factors such as increase in awareness about autoimmune hemolytic anemia therapeutics and blood disorders would create lucrative growth prospects for the Autoimmune Hemolytic Anemia Therapeutics market across Asia-Pacific region.

Major market player included in this report are:

Kezar Life Sciences, Inc.

Amneal Pharmaceuticals, Inc.

F. Hoffmann-La Roche Ltd.

Rigel Pharmaceuticals, Inc.

Baxter International, Inc.

Incyte Corp.

Teva Pharmaceutical Industries Ltd.

Sanofi

Pfizer, Inc.

Mylan NV

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming eight years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within each of the regions and countries involved in the study. Furthermore, the report also caters the detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, the report shall also incorporate available opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Drug Class:

Corticosteroids

Monoclonal Antibodies

Others

By Diseases Type:

Cold Antibody Hemolytic Anemia

Warm Antibody Hemolytic Anemia

By Distribution channel:

Retail pharmacies

Hospital pharmacies

Online pharmacies

By Region:

North America

U.S.

Canada

Europe

UK

Germany

France

Spain

Italy

ROE

Asia Pacific

China

India

Japan

Australia

South Korea

RoAPAC

Latin America

Brazil

Mexico

Rest of the World

Furthermore, years considered for the study are as follows:

Historical year - 2017, 2018

Base year - 2019

Forecast period - 2020 to 2027

Target Audience of the Global Autoimmune Hemolytic Anemia Therapeutics Market in Market Study:

Key Consulting Companies & Advisors

Large, medium-sized, and small enterprises

Venture capitalists

Value-Added Resellers (VARs)

Third-party knowledge providers

Investment bankers

Investors

Table of Contents

Chapter 1. Executive Summary

  • 1.1. Market Snapshot
  • 1.2. Global & Segmental Market Estimates & Forecasts, 2018-2027 (USD Billion)
    • 1.2.1. Autoimmune Hemolytic Anemia Therapeutics Market, by Region, 2018-2027 (USD Billion)
    • 1.2.2. Autoimmune Hemolytic Anemia Therapeutics Market, by Drug Class, 2018-2027 (USD Billion)
    • 1.2.3. Autoimmune Hemolytic Anemia Therapeutics Market, by Disease type, 2018-2027 (USD Billion)
    • 1.2.4. Autoimmune Hemolytic Anemia Therapeutics Market, by Distribution channel, 2018-2027 (USD Billion)
  • 1.3. Key Trends
  • 1.4. Estimation Methodology
  • 1.5. Research Assumption

Chapter 2. Global Autoimmune Hemolytic Anemia Therapeutics Market Definition and Scope

  • 2.1. Objective of the Study
  • 2.2. Market Definition & Scope
    • 2.2.1. Scope of the Study
    • 2.2.2. Industry Evolution
  • 2.3. Years Considered for the Study
  • 2.4. Currency Conversion Ratesx

Chapter 3. Global Autoimmune Hemolytic Anemia Therapeutics Market Dynamics

  • 3.1. Autoimmune Hemolytic Anemia Therapeutics Market Impact Analysis (2018-2027)
    • 3.1.1. Market Drivers
    • 3.1.2. Market Challenges
    • 3.1.3. Market Opportunities

Chapter 4. Global Autoimmune Hemolytic Anemia Therapeutics Market Industry Analysis

  • 4.1. Porter's 5 Force Model
    • 4.1.1. Bargaining Power of Suppliers
    • 4.1.2. Bargaining Power of Buyers
    • 4.1.3. Threat of New Entrants
    • 4.1.4. Threat of Substitutes
    • 4.1.5. Competitive Rivalry
    • 4.1.6. Futuristic Approach to Porter's 5 Force Model (2017-2027)
  • 4.2. PEST Analysis
    • 4.2.1. Political
    • 4.2.2. Economical
    • 4.2.3. Social
    • 4.2.4. Technological
  • 4.3. Investment Adoption Model
  • 4.4. Analyst Recommendation & Conclusion

Chapter 5. Global Autoimmune Hemolytic Anemia Therapeutics Market, by Drug Class

  • 5.1. Market Snapshot
  • 5.2. Global Autoimmune Hemolytic Anemia Therapeutics Market by Drug Class, Performance - Potential Analysis
  • 5.3. Global Autoimmune Hemolytic Anemia Therapeutics Market Estimates & Forecasts by Drug Class 2017-2027 (USD Billion)
  • 5.4. Autoimmune Hemolytic Anemia Therapeutics Market, Sub Segment Analysis
    • 5.4.1. Corticosteroids
    • 5.4.2. Monoclonal Antibodies
    • 5.4.3. Others

Chapter 6. Global Autoimmune Hemolytic Anemia Therapeutics Market, by Disease type

  • 6.1. Market Snapshot
  • 6.2. Global Autoimmune Hemolytic Anemia Therapeutics Market by Disease type, Performance - Potential Analysis
  • 6.3. Global Autoimmune Hemolytic Anemia Therapeutics Market Estimates & Forecasts by Disease type 2017-2027 (USD Billion)
  • 6.4. Autoimmune Hemolytic Anemia Therapeutics Market, Sub Segment Analysis
    • 6.4.1. Cold Antibody Hemolytic Anemia
    • 6.4.2. Warm Antibody Hemolytic Anemia

Chapter 7. Global Autoimmune Hemolytic Anemia Therapeutics Market, by Distribution channel

  • 7.1. Market Snapshot
  • 7.2. Global Autoimmune Hemolytic Anemia Therapeutics Market by Distribution channel, Performance - Potential Analysis
  • 7.3. Global Autoimmune Hemolytic Anemia Therapeutics Market Estimates & Forecasts by Distribution channel 2017-2027 (USD Billion)
  • 7.4. Autoimmune Hemolytic Anemia Therapeutics Market, Sub Segment Analysis
    • 7.4.1. Hospital Pharmacies
    • 7.4.2. Retail Pharmacies
    • 7.4.3. Online Pharmacies

Chapter 8. Global Autoimmune Hemolytic Anemia Therapeutics Market, Regional Analysis

  • 8.1. Autoimmune Hemolytic Anemia Therapeutics Market, Regional Market Snapshot
  • 8.2. North America Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.2.1. U.S. Autoimmune Hemolytic Anemia Therapeutics Market
      • 8.2.1.1. Drug Class breakdown estimates & forecasts, 2017-2027
      • 8.2.1.2. Diseases type breakdown estimates & forecasts, 2017-2027
      • 8.2.1.3. Distribution channel breakdown estimates & forecasts, 2017-2027
    • 8.2.2. Canada Autoimmune Hemolytic Anemia Therapeutics Market
  • 8.3. Europe Autoimmune Hemolytic Anemia Therapeutics Market Snapshot
    • 8.3.1. U.K. Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.3.2. Germany Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.3.3. France Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.3.4. Spain Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.3.5. Italy Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.3.6. Rest of Europe Autoimmune Hemolytic Anemia Therapeutics Market
  • 8.4. Asia-Pacific Autoimmune Hemolytic Anemia Therapeutics Market Snapshot
    • 8.4.1. China Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.4.2. India Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.4.3. Japan Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.4.4. Australia Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.4.5. South Korea Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.4.6. Rest of Asia Pacific Autoimmune Hemolytic Anemia Therapeutics Market
  • 8.5. Latin America Autoimmune Hemolytic Anemia Therapeutics Market Snapshot
    • 8.5.1. Brazil Autoimmune Hemolytic Anemia Therapeutics Market
    • 8.5.2. Mexico Autoimmune Hemolytic Anemia Therapeutics Market
  • 8.6. Rest of The World Autoimmune Hemolytic Anemia Therapeutics Market

Chapter 9. Competitive Intelligence

  • 9.1. Top Market Strategies
  • 9.2. Company Profiles
    • 9.2.1. Kezar Life Sciences, Inc.
      • 9.2.1.1. Key Information
      • 9.2.1.2. Overview
      • 9.2.1.3. Financial (Subject to Data Availability)
      • 9.2.1.4. Product Summary
      • 9.2.1.5. Recent Developments
    • 9.2.2. Amneal Pharmaceuticals, Inc.
    • 9.2.3. F. Hoffmann-La Roche Ltd.
    • 9.2.4. Rigel Pharmaceuticals, Inc.
    • 9.2.5. Baxter International, Inc.
    • 9.2.6. Incyte Corp.
    • 9.2.7. Teva Pharmaceutical Industries Ltd.
    • 9.2.8. Sanofi
    • 9.2.9. Pfizer, Inc.
    • 9.2.10. Mylan NV

Chapter 10. Research Process

  • 10.1. Research Process
    • 10.1.1. Data Mining
    • 10.1.2. Analysis
    • 10.1.3. Market Estimation
    • 10.1.4. Validation
    • 10.1.5. Publishing
  • 10.2. Research Attributes
  • 10.3. Research Assumption

LIST OF TABLES

  • TABLE 1. Global Autoimmune Hemolytic Anemia Therapeutics market, report scope
  • TABLE 2. Global Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by Region 2017-2027 (USD Billion)
  • TABLE 3. Global Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by Drug Class 2017-2027 (USD Billion)
  • TABLE 4. Global Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by Diseases type 2017-2027 (USD Billion)
  • TABLE 5. Global Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by Distribution channel 2017-2027 (USD Billion)
  • TABLE 6. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 7. Global Autoimmune Hemolytic Anemia Therapeutics market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 8. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 9. Global Autoimmune Hemolytic Anemia Therapeutics market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 10. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 11. Global Autoimmune Hemolytic Anemia Therapeutics market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 12. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 13. Global Autoimmune Hemolytic Anemia Therapeutics market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 14. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 15. Global Autoimmune Hemolytic Anemia Therapeutics market by region, estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 16. U.S. Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 17. U.S. Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 18. U.S. Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 19. Canada Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 20. Canada Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 21. Canada Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 22. UK Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 23. UK Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 24. UK Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 25. Germany Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 26. Germany Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 27. Germany Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 28. RoE Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 29. RoE Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 30. RoE Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 31. China Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 32. China Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 33. China Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 34. India Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 35. India Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 36. India Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 37. Japan Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 38. Japan Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 39. Japan Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 40. RoAPAC Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 41. RoAPAC Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 42. RoAPAC Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 43. Brazil Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 44. Brazil Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 45. Brazil Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 46. Mexico Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 47. Mexico Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 48. Mexico Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 49. RoLA Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 50. RoLA Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 51. RoLA Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 52. Row Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts, 2017-2027 (USD Billion)
  • TABLE 53. Row Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 54. Row Autoimmune Hemolytic Anemia Therapeutics market estimates & forecasts by segment 2017-2027 (USD Billion)
  • TABLE 55. List of secondary sources, used in the study of global Autoimmune Hemolytic Anemia Therapeutics market
  • TABLE 56. List of primary sources, used in the study of global Autoimmune Hemolytic Anemia Therapeutics market
  • TABLE 57. Years considered for the study
  • TABLE 58. Exchange rates considered

LIST OF FIGURES

List of figures

  • FIG 1. Global Autoimmune Hemolytic Anemia Therapeutics market, research methodology
  • FIG 2. Global Autoimmune Hemolytic Anemia Therapeutics market, market estimation techniques
  • FIG 3. Global market size estimates & forecast methods
  • FIG 4. Global Autoimmune Hemolytic Anemia Therapeutics market, key trends 2019
  • FIG 5. Global Autoimmune Hemolytic Anemia Therapeutics market, growth prospects 2020-2027
  • FIG 6. Global Autoimmune Hemolytic Anemia Therapeutics market, porters 5 force model
  • FIG 7. Global Autoimmune Hemolytic Anemia Therapeutics market, pest analysis
  • FIG 8. Global Autoimmune Hemolytic Anemia Therapeutics market, value chain analysis
  • FIG 9. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, 2017 & 2027 (USD Billion)
  • FIG 10. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, 2017 & 2027 (USD Billion)
  • FIG 11. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, 2017 & 2027 (USD Billion)
  • FIG 12. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, 2017 & 2027 (USD Billion)
  • FIG 13. Global Autoimmune Hemolytic Anemia Therapeutics market by segment, 2017 & 2027 (USD Billion)
  • FIG 14. Global Autoimmune Hemolytic Anemia Therapeutics market, regional snapshot 2017 & 2027
  • FIG 15. North America Autoimmune Hemolytic Anemia Therapeutics market 2017 & 2027 (USD Billion)
  • FIG 16. Europe Autoimmune Hemolytic Anemia Therapeutics market 2017 & 2027 (USD Billion)
  • FIG 17. Asia pacific Autoimmune Hemolytic Anemia Therapeutics market 2017 & 2027 (USD Billion)
  • FIG 18. Latin America Autoimmune Hemolytic Anemia Therapeutics market 2017 & 2027 (USD Billion)
  • FIG 19. Global Autoimmune Hemolytic Anemia Therapeutics market, company market share analysis (2019)